Advances in the treatment of platinum-resistant ovarian cancer with PARP inhibitors

Abstract

Li Chenxi, Zhao Hongwei. Advances in the treatment of platinum-resistant ovarian cancer with PARP inhibitors[J]. Journal of International Oncology, 2021, 48(3): 180-183.

References29

[1]	Gaona-Luviano P, Medina-Gaona LA, Magaña-Pérez K. Epidemiology of ovarian cancer [J]. Chin Clin Oncol, 2020,9(4):47. DOI: 10.21037/cco-20-34. doi:10.21037/cco
[2]	Pujade-Lauraine E, Combe P. Recurrent ovarian cancer[J]. Ann Oncol, 2016,27 Suppl 1: i63-i65. DOI: 10.1093/annonc/mdw079.
[3]	Scott CL, Swisher EM, Kaufmann SH. Poly (ADP-ribose) polyme-rase inhibitors: recent advances and future development[J]. J Clin Oncol, 2015,33(12):1397-1406. DOI: 10.1200/JCO.2014.58.8848. doi:10.1200/JCO.2014.58.8848pmid:25779564
[4]	李宁, 吴令英. PARP抑制剂在上皮性卵巢癌的应用现状[J]. 实用妇产科杂志, 2020,36(2):88-92.
[5]	Scott LJ. Niraparib: first global approval[J]. Drugs, 2017,77(9):1029-1034. DOI: 10.1007/s40265-017-0752-y.
[6]	Syed YY. Rucaparib: first global approval[J]. Drugs, 2017,77(5):585-592. DOI: 10.1007/s40265-017-0716-2. doi:10.1007/s40265-017-0716-2pmid:28247266
[7]	Deeks ED. Olaparib: first global approval[J]. Drugs, 2015,75(2):231-240. DOI: 10.1007/s40265-015-0345-6. pmid:25616434
[8]	Pujade-Lauraine E, Banerjee S, Pignata S. Management of platinum-resistant, relapsed epithelial ovarian cancer and new drug perspectives[J]. J Clin Oncol, 2019,37(27):2437-2448. DOI: 10.1200/JCO.19.00194. pmid:31403868
[9]	Washington CR, Richardson DL, Moore KN. Olaparib in the treatment of ovarian cancer[J]. Future Oncol, 2019,15(30):3435-3449. DOI: 10.2217/fon-2019-0271. doi:10.2217/fon-2019-0271pmid:31478762
[10]	Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation[J]. J Clin Oncol, 2015,33(3):244-250. DOI: 10.1200/JCO.2014.56.2728. pmid:25366685
[11]	Kim H, George E, Ragland R, et al. Targeting the ATR/CHK1 axis with PARP inhibition results in tumor regression in BRCA-mutant ovarian cancer models[J]. Clin Cancer Res, 2017,23(12):3097-3108. DOI: 10.1158/1078-0432.CCR-16-2273.
[12]	Domchek SM, Aghajanian C, Shapira-Frommer R, et al. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy[J]. Gynecol Oncol, 2016,140(2):199-203. DOI: 10.1016/j.ygyno.2015.12.020.
[13]	Jenner ZB, Sood AK, Coleman RL. Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy[J]. Future Oncol, 2016,12(12):1439-1456. DOI: 10.2217/fon-2016-0002. pmid:27087632
[14]	Sabatucci I, Maltese G, Lepori S, et al. Rucaparib: a new treatment option for ovarian cancer[J]. Expert Opin Pharmacother, 2018,19(7):765-771. DOI: 10.1080/14656566.2018.1464557. doi:10.1080/14656566.2018.1464557pmid:29672168
[15]	Dal Molin GZ, Westin SN, Coleman RL. Rucaparib in ovarian can-cer: extending the use of PARP inhibitors in the recurrent disease[J]. Future Oncol, 2018,14(30):3101-3110. DOI: 10.2217/fon-2018-0215. doi:10.2217/fon-2018-0215pmid:30105925
[16]	Oza AM, Tinker AV, Oaknin A, et al. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from Study 10 and ARIEL2[J]. Gynecol Oncol, 2017,147(2):267-275. DOI: 10.1016/j.ygyno.2017.08.022. pmid:28882436
[17]	Moore KN, Secord AA, Geller MA, et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial[J]. Lancet Oncol, 2019,20(5):636-648. DOI: 10.1016/S1470-2045(19)30029-4. doi:10.1016/S1470-2045(19)30029-4pmid:30948273
[18]	Moore KN, Secord AA, Geller MA, et al. QUADRA: a phase Ⅱ, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: results from the tBRCAmut subset[J]. Ann Oncol, 2018,29(suppl 8):944P.DOI: 10.1093/annonc/mdy285.152.
[19]	Perez-Fidalgo JA, Iglesias M, Bohn U, et al. GEICO1601-ROLANDO: a multicentric single arm phase Ⅱ clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer[J]. Future Sci OA, 2019,5(2):FSO370. DOI: 10.4155/fsoa-2018-0107. pmid:30820349
[20]	Konstantinopoulos PA, Barry WT, Birrer M, et al. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial[J]. Lancet Oncol, 2019,20(4):570-580. DOI: 10.1016/S1470-2045(18)30905-7. doi:10.1016/S1470-2045(18)30905-7pmid:30880072
[21]	薛晨, 赵月, 石光, 等. PD-1/PD-L1抑制剂在卵巢癌中的研究进展[J]. 国际肿瘤学杂志, 2020,47(5):312-315. DOI: 10.3760/cma.j.cn371439-20200321-00026.
[22]	Shen J, Zhao W, Ju Z, et al. PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness[J]. Cancer Res, 2019,79(2):311-319. DOI: 10.1158/0008-5472.CAN-18-1003. doi:10.1158/0008-5472.CAN-18-1003pmid:30482774
[23]	Konstantinopoulos PA, Waggoner S, Vidal GA, et al. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma[J]. JAMA Oncol, 2019,5(8):1141-1149. DOI: 10.1001/jamaoncol.2019.1048. doi:10.1001/jamaoncol.2019.1048
[24]	Varga A, Piha-Paul S, Ott PA, et al. Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: analysis of KEYNOTE-028[J]. Gynecol Oncol, 2019,152(2):243-250. DOI: 10.1016/j.ygyno.2018.11.017. doi:10.1016/j.ygyno.2018.11.017
[25]	Matulonis UA, Shapira-Frommer R, Santin AD, et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase Ⅱ KEYNOTE-100 study[J]. Ann Oncol, 2019,30(7):1080-1087. DOI: 10.1093/annonc/mdz135. doi:10.1093/annonc/mdz135pmid:31046082
[26]	Ivy SP, Liu JF, Lee JM, et al. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer[J]. Expert Opin Investig Drugs, 2016,25(5):597-611. DOI: 10.1517/13543784.2016.1156857. doi:10.1517/13543784.2016.1156857pmid:26899229
[27]	Liu JF, Tolaney SM, Birrer M, et al. A phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer[J]. Eur J Cancer, 2013,49(14):2972-2978. DOI: 10.1016/j.ejca.2013.05.020. doi:10.1016/j.ejca.2013.05.020pmid:23810467
[28]	Liu JF, Barry WT, Birrer M, et al. Overall survival and updated progression-free survival outcomes in a randomized phase Ⅱ study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer[J]. Ann Oncol, 2019,30(4):551-557. DOI: 10.1093/annonc/mdz018. doi:10.1093/annonc/mdz018pmid:30753272
[29]	Boussios S, Karihtala P, Moschetta M, et al. Combined strategies with poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer: a literature review[J]. Diagnostics (Basel), 2019,9(3):87. DOI: 10.3390/diagnostics9030087.

Advances in the treatment of platinum-resistant ovarian cancer with PARP inhibitors

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References29

Related Articles15

Recommended Articles

Metrics

Comments

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Gong Yan, Chen Honglei.Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer[J]. Journal of International Oncology, 2024, 51(3): 186-190.
[3]	Jiang Xi, Wu Yongcun, Liang Yan, Chu Li, Duan Yingxin, Wang Lijun, Huo Junjie.Impact of pembrolizumab combined with chemotherapy on angiogenesis and circulating endothelial cells in patients with advanced non-small cell lung cancer[J]. Journal of International Oncology, 2024, 51(2): 89-94.
[4]	An Rong, Liu Meihua, Wang Peichen, Wang Xiaohui.Research progress of Nrf2 in ovarian cancer[J]. Journal of International Oncology, 2023, 50(8): 493-497.
[5]	Li Chenxi, Zhao Hongwei.Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery[J]. Journal of International Oncology, 2023, 50(6): 342-347.
[6]	Liu Li, Zhu Siqi, Sun Mengying, He Jingdong.Progress of PARP inhibitors in targeted therapy of small cell lung cancer[J]. Journal of International Oncology, 2023, 50(6): 368-372.
[7]	Yang Lirong, Wang Yufeng.Construction of machine learning models for predicting the risk of postoperative distant metastasis recurrence in serous ovarian cancer[J]. Journal of International Oncology, 2023, 50(4): 220-226.
[8]	Fan Shanlin, Wang Pinxiu, Kong Fei, Zhou Yujie, Yuan Wenzhen.Progress in the study of predictors of tumor regression grade after neoadjuvant chemotherapy for gastric cancer[J]. Journal of International Oncology, 2023, 50(2): 112-116.
[9]	Geng Rui, Ma Junqiang, Guo Qiang, Niu Zhaofeng.Tendency of elderly patients with breast cancer to choose comprehensive treatment mode and its influencing factors[J]. Journal of International Oncology, 2023, 50(11): 650-654.
[10]	Sun Qi, Li Wenqian, Xie Youbang, Zhou Houfa.Research progress on the mechanism of bone marrow suppression after chemotherapy[J]. Journal of International Oncology, 2023, 50(1): 33-36.
[11]	Liu Yonghong, Xue Lingbo, Bai Yang, Jin Jian, Zang Chunxia, Zhang Bo, Li Jie.Predictive value of systemic inflammation response index before treatment for pathological complete response in patients with breast cancer undergoing neoadjuvant chemotherapy[J]. Journal of International Oncology, 2022, 49(4): 210-215.
[12]	Zhang Junpeng, Yu Yanyan, Li Baosheng.Mechanism of lncRNA and circRNA regulating the sensitivity of radiotherapy and chemotherapy in esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2022, 49(3): 185-189.
[13]	Liu Xiaojing, Zhu Minghua, Zuo Si, Meng Di, Bi Yan, Wang Wei, Jin Shujuan.Effects of different treatments on prognosis of triple-negative breast cancer[J]. Journal of International Oncology, 2022, 49(1): 33-38.
[14]	Peng Ya, Liu An, Liu Huowang.Inhibitory effect and mechanism of PSD-007 photodynamic therapy on human nasopharyngeal carcinoma transplanted tumors in nude mice[J]. Journal of International Oncology, 2021, 48(3): 136-142.
[15]	Li Zhefeng, Li Jie, Zhao Xiaoting, Yue Wentao.GLDC regulates proliferation and apoptosis of ovarian cancer cells through PI3K/Akt/mTOR pathway[J]. Journal of International Oncology, 2021, 48(12): 716-722.